Emily M. Hsieh

Hematology | Oncology
4650 W Sunset Blvd # 54
Los Angeles, CA 90027

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.

Journal: Blood advances
Published: October 01, 2025

Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies.

Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies.

Journal: Neurology
Published: September 08, 2025

Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group.

Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group.

Journal: Transplantation and cellular therapy
Published: August 04, 2025

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.

Journal: Blood advances
Published: February 11, 2025

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.

Journal: Blood advances
Published: January 28, 2025

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Journal: Blood
Published: September 09, 2024

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults.

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults.

Journal: Blood advances
Published: March 22, 2024

INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.

INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.

Journal: Transplantation and cellular therapy
Published: September 07, 2023

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.

Journal: Transplantation and cellular therapy
Published: May 01, 2023

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.

Journal: Blood advances
Published: May 13, 2022

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 04, 2020

Replacing CAR-T cell resistance with persistence by changing a single residue.

Replacing CAR-T cell resistance with persistence by changing a single residue.

Journal: The Journal of clinical investigation
Published: May 05, 2020
Showing 1-12 of 15

Last Updated: 09/26/2026